Stock Movers Home Depot, AMD Rises; Novo Sinks on Obesity Flop
Feb 24, 2026
Nora Melinda, Bloomberg Television markets correspondent, brings market color and company-specific reporting. She covers Home Depot's sales beat amid macro worries. She explains AMD’s big data-center deal with Meta. She discusses Novo Nordisk’s trial setback and investor calls for strategic shifts.
AI Snips
Chapters
Transcript
Episode notes
Home Depot Sales Beat But Macro Risks Linger
- Home Depot beat key sales metrics in its latest quarter, showing steady demand despite macroeconomic worries.
- Shares rose ~2.3% and are up nearly 12% year-to-date, but analysts question its ability to fully weather real estate headwinds.
Novo Nordisk Lowers Prices After Trial Setbacks
- Novo Nordisk plans U.S. price cuts for Wegovy and Ozempic amid competitive pressure and trial disappointments.
- The cuts aim to lower out-of-pocket costs but fuel investor skepticism and peer pressure on Eli Lilly.
Obesity Drug Rivalry Is Hitting Stocks
- The obesity drug contest between Novo Nordisk and Eli Lilly is intensifying with spillover effects across peers.
- Market reaction shows both companies' stocks falling as investors re-evaluate pricing and competitive dynamics.